Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbCellera Biologics Inc.ABCL · Entity 4118 | Chief Legal Officer | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbCellera Biologics Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2036-01-01 | Direct | 4,646,012 |
Reported balance
After 2026-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 539,265 · Balance 4,646,012 F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 17:10 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 539,265 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001834424-26-000002 · wk-form4_1767633019.xml · derivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,646,012 Underlying: Common Shares · 539,265 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 20:44 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 832,033 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001628280-25-000237 · wk-form4_1735937075.xml · derivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,106,747 Underlying: Common Shares · 832,033 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 14, 2024 Filed Jan 16, 2024 23:21 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 616,333 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001703057-24-000006 · wk-form4_1705447284.xml · derivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,274,714 Underlying: Common Shares · 616,333 shares Expires 2034-01-14 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 17:22 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare Options (right to buy) · Derivative | 346,901 | $0.00 Strike: $13.18 | $0.00 |
DisclosureSEC source: 0001209191-22-059570 · doc4.xml · derivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,658,381 Underlying: Common Shares · 346,901 shares Expires 2032-12-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:55 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare Option (right to buy) · Derivative | 270,680 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068847 · doc4.xml · derivative · entry 3 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,311,480 Underlying: Common Shares · 270,680 shares Expires 2031-12-07 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:01 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | SaleCommon Shares | 1,000,000 | $25.50 | $25,500,000.00 |
DisclosureSEC source: 0000899243-21-022989 · doc4.xml · nonDerivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F2 · kind: The sale of the shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), to the extent of 500 Shares, with the purchase by the Reporting Person of 250 Shares at a price of $20 per share on December 15, 2020, and the purchase by the Reporting Person's spouse of 250 Shares at a price of $20 per share on December 15, 2020, as reported previously on the Reporting Person's Form 4 filed on December 17, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000899243-21-022899 · doc4.xml · derivative · entry 5 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Shares · 250,000 shares Expires 2030-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Previously reported on Form 3 filed on December 11, 2020 and Form 4 filed on December 17, 2020. The vesting schedule was amended such that all of the shares subject to such option were vested as of March 24, 2021. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0000899243-21-022899 · doc4.xml · derivative · entry 4 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Shares · 750,000 shares Expires 2029-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Previously reported on Form 3 filed on December 11, 2020. The vesting schedule was amended as follow: 25% of the shares subject to such option vest and become exercisable on August 22, 2020; 6.25% of the shares subject to such option vest and become exercisable on November 22, 2020 and February 22, 2021; 4.70% of the shares subject to such option vest and become exercisable on on July 1, 2022; 8.9% of the shares subject to such option vest and become exercisable on October 1, 2022; 7.4% of the shares subject to such option vest and become exercisable on January 1, 2023; 10.40% of the shares subject to such option vest and become exercisable on April 1, 2023; 8.90% of the shares subject to such option vest and become exercisable on July 1, 2023 and October 1, 2023; 2.70% of the shares subject to such option vest and become exercisable on January 1, 2024; F2 · derivative.exercise_date: (Continued from footnote 1) and 2.65% of the shares subject to such option vest and become exercisable on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 250,000 | $2.30 | $575,000.00 |
DisclosureSEC source: 0000899243-21-022899 · doc4.xml · nonDerivative · entry 2 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 750,000 | $0.32 | $240,000.00 |
DisclosureSEC source: 0000899243-21-022899 · doc4.xml · nonDerivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 250 | $20.00 | $5,000.00 |
DisclosureSEC source: 0000899243-20-034339 · doc4.xml · nonDerivative · entry 2 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 250 Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 250 | $20.00 | $5,000.00 |
DisclosureSEC source: 0000899243-20-034339 · doc4.xml · nonDerivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
| December 10, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantStock Option (right to buy) · Derivative | 190,800 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034339 · doc4.xml · derivative · entry 4 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,800 Underlying: Common Shares · 190,800 shares Expires 2030-12-10 F5 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 29, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantStock Option (right to buy) · Derivative | 850,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0000899243-20-034339 · doc4.xml · derivative · entry 3 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Shares · 850,000 shares Expires 2030-10-29 F1 · derivative.exercise_price: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F2 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00. F5 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. F1 · derivative.underlying_shares: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F1 · balance_after: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.